1
Neville J Anthony, Robert P Gomez: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, December 29, 1998: US05854264 (93 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


2
Neville J Anthony: Biheteroaryl inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, December 29, 1998: US05854265 (91 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


3
Prasun K Chakravarty, William J Greenlee, Nathan B Mantlo, Arthur A Patchett, Thomas F Walsh: Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists. Merck & Co, Valerie J Camara, Mark R Daniel, Joseph F DiPrima, July 26, 1994: US05332744 (87 worldwide citation)

Substituted Imidazo-fused 6-membered heterocycles of structural formula: ##STR1## wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.


4
Neville J Anthony, Terrence M Ciccarone, Christopher J Dinsmore, Robert P Gomez, Theresa M Williams, George D Hartman: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, January 5, 1999: US05856326 (84 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


5
Gerald S Rork, James D Pipkin: Controlled release drug dispersion delivery device. Merck & Co, Francis P Bigley, Mark R Daniel, Joseph F DiPrima, November 22, 1994: US05366738 (83 worldwide citation)

A device for the controlled delivery of a beneficial agent as a gelatinous dispersion consisting of (i) a core which contains a beneficial agent, a polymer which forms gelatinous microscopic particles upon hydration and if desired an agent to modulate the hydration of the polymer; and (ii) an imperm ...


6
Neville J Anthony, Robert P Gomez, Lekhanh O Tran, Steven D Young: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, July 25, 2000: US06093737 (74 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


7
Michel Gallant, Yves Gareau, Daniel Guay, Marc Labelle, Petpiboon Prasit: Indole derivatives with affinity for the cannabinoid receptor. Merck Frosst Canada, Sylvia A Ayler, Mark R Daniel, July 2, 1996: US05532237 (73 worldwide citation)

Disclosed are indole derivatives having activity on the cannabinoid receptors and the methods of their preparation. The compounds are useful for lowering ocular intra ocular pressure and treating glaucoma because of the activity on the cannabinoid receptor.


8
Victor M Garsky, Deborah Defeo Jones, Dong Mei Feng: Conjugates useful in the treatment of prostate cancer. Merck & Co, David A Muthard, Mark R Daniel, September 7, 1999: US05948750 (69 worldwide citation)

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertroph ...


9
Mark G Bock, Ben E Evans, Roger M Freidinger: Benzodiazepine analogs. Merck & Co, Mark R Daniel, Joseph F DiPrima, June 28, 1994: US05324726 (69 worldwide citation)

Benzodiazepine analogs of the formula: ##STR1## wherein: R.sup.3 is ##STR2## --NH(CH.sub.2).sub.2 --.sub.3 NHCOR.sup.7, ##STR3## or --X.sup.11 NR.sup.18 SO.sub.2 (CH.sub.2).sub.q R.sup.7 ; R.sup.7 is O,S,HH, or NR.sup.15 with the proviso that X.sup.7 can be NR.sup.15 only when R.sup.1 is not H.


10
John R Archer, David E Cumpstey, Richard H Gray, Stephen Owen: System and method for automatically feeding, inspecting and diverting tablets for continuous filling of tablet containers. Merck & Co, Francis P Bigley, Mark R Daniel, June 4, 1996: US05522512 (67 worldwide citation)

A system and method for automatically feeding, inspecting and diverting tablets for continuous filling of tablet containers includes a tablet conveyor system which divides the tablets in a plurality of tablet streams for inspection by color, size and shape. Following the tablet inspection, each tabl ...